 The FDA approved a new Alzheimer's drug. It's made by Eli Lilly, a company based in Indianapolis. It's been shown in clinical trials to modestly slow a decline in memory and thinking abilities, and it will be sold under the brand name Kisumla. It is a monoclonal antibody infusion given every four weeks, and it works by targeting amyloid in the brain,